Press release for the Un-audited Financial Results for the quarter ended on 30 June 2025
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences, a Hyderabad-based CRDMO, posted a strong Q1FY26 with revenue from operations at ₹496 Cr, up 77% YoY from ₹280 Cr in Q1FY25, led by 113% growth in CDMO and 38% growth in Discovery. EBITDA jumped to ₹125 Cr from ₹31 Cr (a 305% increase), with EBITDA margin expanding by 14 percentage points to 25%. Profit After Tax (PAT) swung to a profit of ₹60 Cr from a loss of ₹13 Cr in Q1FY25, while PAT margin improved to 12%. The company invested ₹134 Cr in capital expenditure during the quarter and expanded its manufacturing capacity to ~700 KL with the launch of Bidar Unit IV. It also inaugurated a new Peptide Research Center and a 10,300 sq. ft. Biology facility in Hyderabad, and broke ground on a new Process R&D Block.
Strong across-the-board growth with sharp margin expansion and a turnaround to profit signals robust operational momentum, which is likely to be viewed positively by the market. Heavy capex on capacity and R&D infrastructure points to management confidence in sustained growth, though it may pressure near-term returns.